Clinical Trials Logo

Hemoglobinuria, Paroxysmal clinical trials

View clinical trials related to Hemoglobinuria, Paroxysmal.

Filter by:

NCT ID: NCT06028594 Available - Clinical trials for Paroxysmal Nocturnal Hemoglobinuria

Compassionate Use of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria

Start date: n/a
Phase:
Study type: Expanded Access

This program is designed to provide access to pozelimab and cemdisiran and document the long-term safety of pozelimab and cemdisiran combination therapy in patients with paroxysmal nocturnal hemoglobinuria (PNH). PNH is a rare immune disease that causes red blood cells in your body to break apart.

NCT ID: NCT05982938 Available - Clinical trials for Paroxysmal Nocturnal Hemoglobinuria

Danicopan Early Access Program

Start date: n/a
Phase:
Study type: Expanded Access

This is an EAP, designed to provide early access to danicopan for participants with PNH experiencing clinically significant EVH who have failed, not tolerated, or are unable to receive other approved treatments; in the Treating Physician's opinion, the participant is not eligible for or is not able to participate in an ongoing clinical trial of danicopan or a comparable treatment; and according to the Treating Physician, the benefit of danicopan treatment outweighs the potential risks.

NCT ID: NCT05972967 Recruiting - Clinical trials for Paroxysmal Nocturnal Hemoglobinuria

Safety and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Patients With a Sub-optimal Response to Ravulizumab

Start date: March 27, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of OMS906 for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in patients who have a sub-optimal response to ravulizumab.

NCT ID: NCT05889299 Recruiting - Clinical trials for Paroxysmal Nocturnal Hemoglobinuria

Study of the Safety and Efficacy of OMS906 in Patients With Paroxysmal Nocturnal Hemoglobinuria

Start date: December 9, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH).

NCT ID: NCT05886244 Active, not recruiting - Clinical trials for Paroxysmal Nocturnal Hemoglobinuria

Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) in China

Soliris
Start date: July 5, 2023
Phase: Phase 3
Study type: Interventional

This is a Phase 3b, single-arm, open-label, multicenter study to evaluate the efficacy, safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of eculizumab in adult participants with paraxysmal noturnal hemoglobinuria (PNH) in China.

NCT ID: NCT05876312 Recruiting - Clinical trials for Paroxysmal Nocturnal Hemoglobinuria (PNH)

Safety, Tolerability, PK and PD of ADX-038 in HV and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients

PNH
Start date: July 3, 2023
Phase: Phase 1
Study type: Interventional

The first-in-human Phase 1 study described herein will evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in both healthy volunteers (HV) and in patients with paroxysmal nocturnal hemoglobinuria (PNH).

NCT ID: NCT05842486 Completed - Clinical trials for Paroxysmal Nocturnal Hemoglobinuria

Hematological Response in Patients With Paroxysmal Nocturnal Hemoglobinuria Treated With Anti-C5 Antibody: an External Control Arm Study for Iptacopan Use in Anti-C5 naïve Patients

APPEX
Start date: January 18, 2023
Phase:
Study type: Observational

The aim of this non-interventional secondary use of data study is to evaluate hematological response in patients with paroxysmal nocturnal hemoglobinuria and anemia in the 6-month period after initiation of anti-C5 antibody treatment using real-world data obtained from multiple datasets. The results will be used to contextualize results from the APPOINT-PNH (NCT04820530) trial with iptacopan.

NCT ID: NCT05828485 Completed - Clinical trials for Paroxysmal Nocturnal Hemoglobinuria

Effect of Food on Pharmacokinetics of MY008211A Tablets in Healthy Adult Subjects

Start date: September 26, 2022
Phase: Phase 1
Study type: Interventional

This was a single-center, single-dose, open-label clinical study. 12 subjects were randomly assigned in a 1:1 ratio to one of the following dosing sequences (sequence 1: AB; Sequence 2: BA). Each dosing sequence consisted of two cycles, one dose per cycle, with a 5-day washout period between doses.

NCT ID: NCT05828472 Completed - Clinical trials for Paroxysmal Nocturnal Hemoglobinuria

A Study of Multiple Ascending Doses MY008211A in Healthy Adults

Start date: January 10, 2023
Phase: Phase 1
Study type: Interventional

This is a single-center, randomized, double-blind, placebo-controlled, dose-escalation, and multiple-dose study to evaluate safety, tolerability, PK and PD of MY008211A Tablets in healthy subjects.

NCT ID: NCT05794425 Recruiting - Clinical trials for Bone Marrow Failure Disorders

Clinical Study of UCB Combined With UC-MSCs in the Treatment of Bone Marrow Failure Disorders

Start date: August 1, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The multicenter collaborative clinical study conducted a systematic clinical observation in the treatment of bone marrow failure diseases via UCB&UC-MSCs , in order to observe its clinical efficacy and safety.